ILLEGAL OR LEGITIMATE USE? PRECURSOR COMPOUNDS TO AMPHETAMINE AND METHAMPHETAMINE

REFERENCES

• Ellenhorn M., Schonwald S., Ordog G., Wasserberger J. Ellenhorn's Medical Toxicology—Diagnosis and Treatment of Human Poisoning. Williams & Wilkins, Baltimore, MD 1997
   Google Scholar
• Physician's Desk Reference. 50th ed., Medical Economics Company, Montvale, NJ 1996
   Google Scholar
• Cody J. Metabolic precursors to amphetamine and methamphetamine. Forensic Sci. Rev. 1993; 5: 109–127
   Google Scholar
• Akintonwa D. A. Mechanistic biotransformations of some amphetamine drugs. J. Theoret. Biol. 1986; 120: 303–308
   PubMed Web of Science ®Google Scholar
• Caldwell J. Amphetamines and Related Stimulants: Chemical, Biological, Clinical and Sociological Aspects. CRC Press, Boca Raton, FL 1980
   Google Scholar
• Caldwell J. The metabolism of amphetamines in mammals. Drug Metab. Rev. 1976; 5: 219–280
   PubMed Web of Science ®Google Scholar
• Cody J. Issues pertaining to monitoring the abuse of amphetamines in workplace drug testing. Forensic Sci. Rev. 1994; 6: 81–96
   Google Scholar
• Foltz R., Fentiman A. GC/MS Assays for Abused Drugs in Body Fluids. NIDA Research Monograph 32, NIDA, U.S. Department of Health and Human Services, Rockville, MD 1980
   Google Scholar
• Beckett A., Rowland M., Turner P. Influence of urinary pH on excretion of amphetamine. Lancet 1965; 1: 303
   PubMed Web of Science ®Google Scholar
• Beckett A. H., Rowland M. Urinary excretion of methylamphetamine in man. Nature 1965; 206: 1260–1261
   PubMed Web of Science ®Google Scholar
• Beckett A. H., Rowland M. Urinary excretion kinetics of amphetamine in man. J. Pharm. Pharmacol. 1965; 17: 628–639
   PubMed Web of Science ®Google Scholar
• Caldwell J., Dring L. G., Williams R. T. Metabolism of (14C)methamphetamine in man, the guinea pig and the rat. Biochem. J. 1972; 129: 11–22
   PubMed Web of Science ®Google Scholar
• Beckett A. H., Brookes L. G., Shenoy E. V. Urinary excretion of the drug and its main metabolite in man, after the administration of (plus or minus)-, (plus)- and (minus)-ethylamphetamine. J. Pharm. Pharmacol. 1969; 21(Suppl)151S
   PubMedGoogle Scholar
• Beckett A. H., Haya K. The stereoselective metabolism of ethylamphetamine with fortified rabbit liver homogenates. Xenobiotica 1978; 8: 85–96
   PubMed Web of Science ®Google Scholar
• Beckett A. H., Shenoy E. V., Salmon J. A. The influence of replacement of the N-ethyl group by the cyanoethyl group on the absorption, distribution and metabolism of (plus or minus)-ethylamphetamine in man. J. Pharm. Pharmacol. 1972; 24: 194–202
   PubMed Web of Science ®Google Scholar
• Beckett A. H., Shenoy E. V. B. The effect of N-alkyl chain length and stereochemistry on the absorption, metabolism and urinary excretion of N-alkylamphetamines in man. J. Pharm. Pharmacol. 1973; 25: 793–799
   PubMed Web of Science ®Google Scholar
• Beckett A. H., Salmon J. A., Mitchard M. The relation between blood levels and urinary excretion of amphetamine under controlled acidic and under fluctuating urinary pH values using [14C] amphetamine. J. Pharm. Pharmacol. 1969; 21: 251–258
   PubMed Web of Science ®Google Scholar
• Davis J. M., Kopin I. J., Lemberger L., Axelrod J. Effects of urinary pH on amphetamine metabolism. Ann. NY Acad. Sci. 1971; 179: 493–501
   PubMed Web of Science ®Google Scholar
• Gunne L. M. The urinary output of d- and l-amphetamine in man. Biochem. Pharmacol. 1967; 16: 863–869
   PubMed Web of Science ®Google Scholar
• Wan S., Martin S., Azarnoff D. Kinetics, salivary excretion of amphetamine isomers, and effect of pH. Clin. Pharmacol. Therap. 1978; 23: 585–590
   PubMed Web of Science ®Google Scholar
• Baselt R., Cravey R. Disposition of Toxic Drugs and Chemicals in Man. Biomedical Publications, Davis, CA 1994
   Google Scholar
• Dring L. G., Smith R. L., Williams R. T. The metabolic fate of amphetamine in man and other species. Biochem. J. 1970; 116: 425–435
   PubMed Web of Science ®Google Scholar
• Beckett A. H., al Sarraj S. M. The metabolism of (+)- and (−)-amphetamine and (+)- and (−)-dimethylamphetamine in rabbits in vivo. Biochem. J. 1972; 130: 14P
   PubMed Web of Science ®Google Scholar
• CodyJ T., Schwarzhoff R. Interpretation of methamphetamine and amphetamine enantiomer data. J. Anal. Toxicol. 1993; 17: 321–326
   PubMed Web of Science ®Google Scholar
• Hornbeck C. L., Czarny R. J. Retrospective analysis of some L-methamphetamine/L-amphetamine urine data. J. Anal. Toxicol. 1993; 17: 23–25
   PubMed Web of Science ®Google Scholar
• Hutchaleelaha A., Sukbuntherng J., Chow H. H., Mayersohn M. Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats. Drug Metab. Dispos. 1994; 22: 406–411
   PubMed Web of Science ®Google Scholar
• Jori A., Caccia S., de Ponte P. Differences in the availability of d- and l-enantiomers after administration of racemic amphetamine to rats. Xenobiotica 1978; 8: 589–595
   PubMed Web of Science ®Google Scholar
• Cooke B. J. Chirality of methamphetamine and amphetamine from workplace urine samples. J. Anal. Toxicol. 1994; 18: 49–51
   PubMed Web of Science ®Google Scholar
• Kraemer T., Maurer H. H. Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine. J. Chromatogr. B 1998; 713: 163–187
   PubMed Web of Science ®Google Scholar
• Schlesser J. Drugs Available Abroad—Guide to Therapeutic Drugs Available and Approved Outside the U.S. MEDEX Books, Detroit, MI 1991
   Google Scholar
• Meyer-Probst B., Vehreschild T. Influencing the lack of concentration in hyperkinetic school children with Aponeuron. Psychiatr. Neurol. Med. Psychol. 1976; 28: 491–499
   PubMedGoogle Scholar
• Harris L. S. The stimulants and hallucinogens under consideration: A brief overview of their chemistry and pharmacology. Drug Alcohol Depend. 1986; 17: 107–118
   PubMed Web of Science ®Google Scholar
• Besserer K. Analysis of alpha-phenyl-alpha-N-(beta-phenylisopropyl)-aminoacetonitrile. Drug Res. 1972; 22: 1737–1738
   Web of Science ®Google Scholar
• Honecker H. Studies on the CNS-availability of amphetamine from amphetaminil. Int. J. Clin. Pharmacol. Biopharm. 1975; 12: 121–128
   PubMedGoogle Scholar
• Remberg G., Marsel J., Doring G., Spiteller G. Amphetamine—A metabolite of AN 1. A contribution to the problems of doping analyses. Arch. Toxikol. 1972; 29: 153–157
   PubMedGoogle Scholar
• Beyer K., Strassner W., Klinge D. Untersuchungen über Amphetaminil. Dtsch. Apoth. Ztg. 1971; 111: 677–680
   Google Scholar
• Hoffmann H. Zur Frage der Stabilität von Amphetaminil. Dtsch. Apoth. Ztg. 1971; 111: 680–680
   Google Scholar
• Honecker V H., Coper H. Stability of amphetaminil. 1. In-vitro studies. Drug Res. 1975; 25: 442–445
   Web of Science ®Google Scholar
• Silverstone T. Clinical use of appetite suppressants. Drug Alcohol Depend. 1986; 17: 151–167
   PubMed Web of Science ®Google Scholar
• Silverstone T. Appetite suppressants. A review. Drugs 1992; 43: 820–836
   PubMed Web of Science ®Google Scholar
• Beckett A. H., Tucker G. T., Moffat A. C. Routine detection and identification in urine of stimulants and other drugs, some of which may used to modify performance in sport. J. Pharm. Pharmacol. 1967; 19: 273–294
   PubMed Web of Science ®Google Scholar
• Budd R., Jain N. Metabolism and excretion of benzphetamine. J. Anal. Toxicol. 1978; 2: 241
   Web of Science ®Google Scholar
• Marsel J., Doring G., Remberg G., Spiteller G. Methamaphetamine—A metabolite of the anorectics; Benzphtamine and furfenorex. Z. Rechtsmed 1972; 70: 245–250
   PubMedGoogle Scholar
• Inoue T., Suzuki S., Niwaguchi T. The metabolism of 1-phenyl-2-(N-methyl-N-benzylamino)propane (benzphetamine) in vitro in rat. Xenobiotica 1983; 13: 241–249
   PubMed Web of Science ®Google Scholar
• Niwaguchi T., Inoue T., Suzuki S. The metabolism of 1-phenyl-2-(N-methyl-N-benzylamino)propane (benzphetamine) in vivo in the rat. Xenobiotica 1982; 12: 617–625
   PubMed Web of Science ®Google Scholar
• Inoue T., Suzuki S. The metabolism of 1-phenyl-2-(N-methyl-N-benzylamino)propane (benzphetamine) and 1-phenyl-2-(N-methyl-N-furfurylamino)propane (furfenorex) in man. Xenobiotica 1986; 16: 691–698
   PubMed Web of Science ®Google Scholar
• Cody J. T., Valtier S. Detection of amphetamine and methamphetamine following administration of benzphetamine. J. Anal. Toxicol. 1998; 22: 299–309
   PubMed Web of Science ®Google Scholar
• Brooks J. P., Phillips M., Stafford D. T., Bell J. S. A case of benzphetamine poisoning. Am. J. Forensic Med. Pathol. 1982; 3: 245–247
   PubMed Web of Science ®Google Scholar
• Franceschini A., Duthel J. M., Vallon J. J. Specific detection of urinary sympathomimetic amines for control of anti-doping by gas chromatography–mass spectroscopy. J. Chromatogr. 1991; 541: 109–120
   PubMed Web of Science ®Google Scholar
• Kikura R., Nakahara Y. Hair analysis for drugs of abuse. XI. Disposition of benzphetamine and its metabolites into hair and comparison of benzphetamine use and methamphetamine use by hair analysis. Biol. Pharm. Bull. 1995; 18: 1694–1699
   PubMed Web of Science ®Google Scholar
• Young R., Darmani N. A., Elder E. L., Dumas D., Glennon R. A. Clobenzorex: Evidence for amphetamine-like behavioral actions. Pharmacol. Biochem. Behav. 1997; 56: 311–316
   PubMed Web of Science ®Google Scholar
• Tarver J. A. Amphetamine-positive drug screens from use of clobenzorex hydrochlorate. J. Anal. Toxicol. 1994; 18: 183
   PubMed Web of Science ®Google Scholar
• Glasson B., Benakis A., Thomasset M. Localisation, distribution, excretion and metabolism of the new, C14-labelled appetite depressant clobenzorex hydrochloride. Drug Res. 1971; 21: 1985–1992
   Google Scholar
• Maurer H. H., Kraemer T., Ledvinka O., Schmitt C. J., Weber A. A. Gas chromatography–mass spectrometry (GC–MS) and liquid chromatography–mass spectrometry (LC–MS) in toxicological analysis. Studies on the detection of clobenzorex and its metabolites within a systematic toxicological analysis procedure by GC–MS and by immunoassay and studies on the detection of alpha- and beta-amanitin in urine by atmospheric pressure ionization electrospray LC–MS. J. Chromatogr. B 1997; 689: 81–89
   PubMedGoogle Scholar
• Nakahara Y., Kikura R. Hair analysis for drugs of abuse. XIII. Effect of structural factors on incorporation of drugs into hair: The incorporation rates of amphetamine analogs. Arch. Toxicol. 1996; 70: 841–849
   PubMed Web of Science ®Google Scholar
• Birkmayer W. Deprenyl (selegiline) in the treatment of Parkinson's disease. Acta Neurol. Scand. 1983; 5(Suppl)103–105
   Google Scholar
• Knoll J. The pharmacology of (−)deprenyl. J. Neural Transmiss. 1986; 22(Suppl)75–89
   Google Scholar
• Knoll J. The pharmacology of selegiline ((−)deprenyl). New aspects. Acta Neurol. Scand. 1989; 126(Suppl)83–91
   Google Scholar
• Mann J. J., Aarons S. F., Wilner P. J., Keilp J. G., Sweeney J. A., Pearlstein T., Frances A. J., Kocsis J. H., Brown R. P. A controlled study of the antidepressant efficacy and side effects of (−)-deprenyl. A selective monoamine oxidase inhibitor. Arch. Gen. Psychiatry 1989; 46: 45–50
   PubMed Web of Science ®Google Scholar
• Salonen J. S. Determination of the amine metabolites of selegiline in biological fluids by capillary gas chromatography. J. Chromatogr. 1990; 527: 163–168
   PubMed Web of Science ®Google Scholar
• Philips S. R. Amphetamine, p-hydroxyamphetamine and beta-phenethylamine in mouse brain and urine after (−)- and (+)-deprenyl administration. J. Pharm. Pharmacol. 1981; 33: 739–741
   PubMed Web of Science ®Google Scholar
• Yoshida T., Yamada Y., Yamamoto T., Kuroiwa Y. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: Relationship of metabolism to (MAO) B inhibitory potency. Xenobiotica 1986; 16: 129–136
   PubMed Web of Science ®Google Scholar
• Karoum F., Chuang L. W., Eisler T., Calne D. B., Liebowitz M. R., Quitkin F. M., Klein D. F., Wyatt R. J. Metabolism of (−)deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: A biochemical assessment. Neurology 1982; 32: 503–509
   PubMed Web of Science ®Google Scholar
• Reynolds G. P., Elsworth J. D., Blau K., Sandler M., Lees A. J., Stern G. M. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br. J. Clin. Pharmacol. 1978; 6: 542–544
   PubMed Web of Science ®Google Scholar
• Reynolds G. P., Riederer P., Sandler M. 2-Phenylethylamine and amphetamine in human brain: Effects of L- deprenyl in Parkinson's disease. Biochem. Soc. Trans. 1979; 7: 143–145
   PubMed Web of Science ®Google Scholar
• Reynolds G. P., Riederer P., Sandler M., Jellinger K., Seemann D. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (−)deprenyl administration. J. Neural Transmiss. 1978; 43: 271–277
   PubMed Web of Science ®Google Scholar
• Shulz R., Antonin K., Hoffmann E., Jedrychowski M., Nilsson E., Schick C., Bieck P. Clin. Pharmacol. Ther. 1989; 46: 528
   PubMed Web of Science ®Google Scholar
• Meeker J. E., Reynolds P. C. Postmortem tissue methamphetamine concentrations following selegiline administration. J. Anal. Toxicol. 1990; 14: 330–331
   PubMed Web of Science ®Google Scholar
• Juvancz Z., Ratonyi I., Toth A., Vajda M. Chromatographic determination of nanogram levels of 2-(methylpropargylamino)-1-phenylpropane (Jumex, Deprenyl) in plasma. J. Chromatogr. 1984; 286: 363–369
   Web of Science ®Google Scholar
• Cedarbaum J. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin. Pharmacokinet. 1987; 13: 141–178
   PubMed Web of Science ®Google Scholar
• La Croix R., Pianezzola E., Strolin M. Benedetti, Sensitive high-performance liquid chromatographic method for the determination of the three main metabolites of selegiline (L-deprenyl) in human plasma. J. Chromatogr. B 1994; 656: 251–258
   PubMedGoogle Scholar
• Lengyel J., Magyar K., Hollosi I., Bartok T., Bathori M., Kalasz H., Furst S. Urinary excretion of deprenyl metabolites. J. Chromatogr. A 1997; 762: 321–326
   PubMed Web of Science ®Google Scholar
• Maurer H. H., Kraemer T. Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography–mass spectrometry (GC–MS) and differentiation by enantioselective GC–MS of the intake of selegiline from abuse of methamphetamine or amphetamine. Arch. Toxicol. 1992; 66: 675–678
   PubMed Web of Science ®Google Scholar
• Szebeni G., Lengyel J., Szekacs G., Magyar K., Gaal J., Szatmari I. Gas chromatographic procedure for simultaneous determination of selegiline metabolites, amphetamine, methamphetamine and demethyl–deprenyl in pig plasma. Acta Physiol. Hung. 1995; 83: 135–141
   PubMedGoogle Scholar
• Reimer M. L., Mamer O. A., Zavitsanos A. P., Siddiqui A. W., Dadgar D. Determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. Biol. Mass. Spectrom. 1993; 22: 235–242
   PubMedGoogle Scholar
• Heinonen E. H., Myllyla V., Sotaniemi K., Lamintausta R., Salonen J. S., Anttila M., Savijarvi M., Kotila M., Rinne U. K. Pharmacokinetics and metabolism of selegiline. Acta Neurol. Scand. 1989; 126(Suppl)93–99
   Google Scholar
• Heinonen E. H., Anttila M. I., Lammintausta R. A. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin. Pharmacol. Ther. 1994; 56: 742–749
   PubMed Web of Science ®Google Scholar
• Kikura R., Nakahara Y. Hair analysis for drugs of abuse. IX. Comparison of deprenyl use and methamphetamine use by hair analysis. Biol. Pharm. Bull. 1995; 18: 267–272
   PubMed Web of Science ®Google Scholar
• Inoue T., Suzuki S. The metabolism of dimethylamphetamine in rat and man. Xenobiotica 1987; 17: 965–971
   PubMed Web of Science ®Google Scholar
• Makino Y., Higuchi T., Ohta S., Hirobe M. Identification and quantification of p-hydroxyethylamphetamine as a novel metabolite of ethylamphetamine in rat by gas chromatography–mass spectrometry. Forensic Sci. Int. 1989; 41: 83–91
   PubMed Web of Science ®Google Scholar
• Beckett A. H., Haya K. The identification and quantitation of the major metabolites of ethylamphetamine, produced by rabbit liver microsomal preparations. J. Pharm. Pharmacol. 1977; 29: 89–95
   PubMed Web of Science ®Google Scholar
• Delbeke F. T., Debackere M. The influence of diuretics on the excretion and metabolism of doping agents. III. Etilamfetamine. Drug Res. 1986; 36: 1413–1416
   Web of Science ®Google Scholar
• Nagai T., Kamiyama S., Matsushima K. Analysis of time-lapse changes of d- and l-enantiomers of racemic ethylamphetamine and stereoselective metabolism in rat urine by HPLC determination. J. Anal. Toxicol. 1995; 19: 225–228
   PubMed Web of Science ®Google Scholar
• Nagai T., Kanaya H., Matsushima K., Kamiyama S. Time-lapse changes of d- and l-enantiomers of racemic (dl)-ethylamphetamine in human urine. J. Anal. Toxicol. 1997; 21: 112–115
   PubMed Web of Science ®Google Scholar
• Reynolds J. The Martindale: The Extra Pharmacopoeia. Pharmaceutical Press, London 1996
   Google Scholar
• Mrongovius R., Neugebauer M., Rucker G. Analgesic activity and metabolism in the mouse of morazone, famprofazone and related pyrazolones. Eur. J. Med. Chem. Chim. Therap. 1984; 19: 161–166
   Web of Science ®Google Scholar
• Neugebauer M. Some new urinary metabolites of famprofazone and morazone in man. J. Pharm. Biomed. Anal. 1984; 2: 53–60
   PubMedGoogle Scholar
• Oh E. S., Hong S. K., Kang G. I. Plasma and urinary concentrations of methamphetamine after oral administration of famprofazone to man. Xenobiotica 1992; 22: 377–384
   PubMed Web of Science ®Google Scholar
• Yoo Y., Chung H., Choi H. Urinary methamphetamine concentration following famprofazone administration. J. Anal. Toxicol. 1994; 18: 265–268
   PubMed Web of Science ®Google Scholar
• Cody J. T. Enantiomeric composition of amphetamine and methamphetamine derived from the precursor compound famprofazone. Forensic Sci. Int. 1996; 80: 189–199
   PubMed Web of Science ®Google Scholar
• Shin H. S. Stereoselective metabolism of famprofazone in humans: N-dealkylation and beta- and p-hydroxylation. Chirality 1997; 9: 52–58
   PubMed Web of Science ®Google Scholar
• Musshoff F., Kraemer T. Identification of famprofazone ingestion. Int. J. Legal Med. 1998; 111: 305–308
   PubMed Web of Science ®Google Scholar
• Shin H. S., Park J. S., Park P. B., Yun S. J. Detection and identification of famprofazone and its metabolite in human urine. J. Chromatogr. B 1994; 661: 255–261
   PubMedGoogle Scholar
• Mallol J., Pitarch L., Coronas R., Pons A. J. Determination of dl-fencamine in rat and human urine. Drug Res. 1974; 24: 1301–1304
   Web of Science ®Google Scholar
• Kristen G., Schaefer A., von Schlichtegroll A. Fenetylline: Therapeutic use, misuse and/or abuse. Drug Alcohol Depend. 1986; 17: 259–271
   PubMed Web of Science ®Google Scholar
• Ellison T., Levy L., Bolger J. W., Okun R. The metabolic fate of 3H-fenetylline in man. Eur. J. Pharmacol. 1970; 13: 123–128
   PubMed Web of Science ®Google Scholar
• Iffland R. Urine levels of fenethylline and amphetamine after administration of Captagon. Arch. Kriminol. 1982; 169: 81–88
   PubMedGoogle Scholar
• Goenechea S., Brzezinka H. Detection and identification of a new metabolite of fenethylline. Arch. Kriminol. 1984; 173: 97–102
   Google Scholar
• Nickel B., Niebch G., Peter G., von Schlichtegroll A., Tibes U. Fenetylline: New results on pharmacology, metabolism and kinetics. Drug Alcohol Depend. 1986; 17: 235–257
   PubMed Web of Science ®Google Scholar
• Rücker G., Neugebauer M., Heiden P. G. The biotransformation of fenetylline. Drug Res. 1988; 38: 497–501
   Web of Science ®Google Scholar
• Yoshimura H., Yoshimitsu T., Yamada H., Koga N., Oguri K. Metabolic fate of fenetylline in rat and man. Xenobiotica 1988; 18: 929–940
   PubMed Web of Science ®Google Scholar
• Tognoni G., Morselli P. L., Garattini S. Amphetamine concentrations in rat brain and human urine after fenproporex administration. Eur. J. Pharmacol. 1972; 20: 125–126
   PubMed Web of Science ®Google Scholar
• Nazarali A. J., Baker G. B., Coutts R. T., Pasutto F. M. Amphetamine in rat brain after intraperitoneal injection of N-alkylated analogues. Prog. Neuropsychopharmacol. Biol. Psychiatry 1983; 7: 813–816
   PubMed Web of Science ®Google Scholar
• Coutts R. T., Nazarali A. J., Baker G. B., Pasutto F. M. Metabolism and disposition of N-(2-cyanoethyl)amphetamine (fenproporex) and amphetamine: Study in the rat brain. Can. J. Physiol. Pharmacol. 1986; 64: 724–728
   PubMed Web of Science ®Google Scholar
• Cody J. T., Valtier S. Detection of amphetamine following administration of fenproporex. J. Anal. Toxicol. 1996; 20: 425–431
   PubMed Web of Science ®Google Scholar
• Boissier J. R., Hirtz J., Dumont C., Gerardin A. Metabolism of (+) N-methyl N-(furyl-2methyl) phenylisopropylamine cyclohexylsulfamate (furfenonex cyclohexylsulfamate) in rats. Ann. Pharm. Fr. 1968; 26: 215–226
   PubMed Web of Science ®Google Scholar
• Inoue T., Yasuda T., Suzuki S., Kishi T., Niwaguchi T. The metabolism of 1-phenyl-2-(N-methyl-N-furfurylamino)propane (furfenorex) in the rat in vivo and in vitro. Xenobiotica 1986; 16: 109–121
   PubMed Web of Science ®Google Scholar
• Beyer G., Huth K., Müller G. M., Niemoller H., Raisp I., Vorberg G. The treatment of obesity with the appetite curbing agent Mefenorex. Med. Welt. 1980; 31: 306–309
   PubMed Web of Science ®Google Scholar
• Blum J. E. Experimental studies with the new appetite depressant N-(3-chlorpropyl)-1-methyl-2-phenylethylamine hydrochloride (Ro 4-5282). Drug Res. 1969; 19: 748–755
   Web of Science ®Google Scholar
• Engel J., Kristen G., Schaefer A., von Schlichtegroll A. Mefenorex (Rondimen). Drug Alcohol Depend. 1986; 17: 229–234
   PubMed Web of Science ®Google Scholar
• Williams R., Caldwell J., Dring L. Comparative metabolism of some amphetamines in various species. Frontiers in Catecholamine Research, E. Usdin, S. Snyder. Pergamon Press, New York 1973; 927
   Google Scholar
• Rendic S., Slavica M., Saric M. Medic. Urinary excretion and metabolism of orally administered mefenorex. Eur. J. Drug Metab. Pharmacokinet. 1994; 19: 107–117
   PubMed Web of Science ®Google Scholar
• Kraemer T., Vernaleken I., Maurer H. Studies on the metabolism and toxicological detection of the amphetamine-like anoretic mefenorex in human urine by gas chromatography–mass spectrometry and fluorescence polarization immunoassay. J. Chromatogr. B 1997; 702: 93–102
   PubMedGoogle Scholar
• Vinar O., Klein D. F., Potter W. Z., Gause E. M. A survey of psychotropic medications not available in the United States. Neuropsychopharmacology 1991; 5: 201–217
   PubMed Web of Science ®Google Scholar
• Polgar M., Vereczkey L., Szporny L., Czira G., Tamas J., Baitz E. Gacs, Holly S. Metabolism of mesocarb in the rat. Xenobiotica 1979; 9: 511–519
   PubMed Web of Science ®Google Scholar
• Pyo H., Park S. J., Park J., Yoo J. K., Yoon B. Analysis of mesocarb analogues in urine and plasma of rats by high-performance liquid chromatography and thermospray liquid chromatography–mass spectrometry. J. Chromatogr. B 1996; 687: 261–269
   PubMedGoogle Scholar
• Leary W. P., Asmal A. C., Williams P. Prenylamine lactate in the treatment of angina pectoris. Curr. Therap. Res. Clin. Exp. 1976; 19: 180–184
   PubMed Web of Science ®Google Scholar
• Lamers J. M., Cysouw K. J., Verdouw P. D. Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem. Pharmacol. 1985; 34: 3837–3843
   PubMed Web of Science ®Google Scholar
• Manning A., Crome R., Isted K., Coltart D., Hearse D. Reperfusion-induced ventricular fibrillation. Modification by pharmacological agents. Adv. Mycardiol. 1985; 6: 515–528
   PubMedGoogle Scholar
• Giannella E., Masini E., Palmerani B., Pistelli A., Mannaioni P. Modulation of anaphylactic histamine release by calcium channel agonists and antagonists. Agents Actions 1988; 23: 185–187
   PubMedGoogle Scholar
• Gietl Y., Spahn H., Knauf H., Mutschler E. Single- and multiple-dose pharmacokinetics of R-(−)- and S-(+)-prenylamine in man. Eur. J. Clin. Pharmacol. 1990; 38: 587–593
   PubMed Web of Science ®Google Scholar
• Paar W. D., Brockmeier D., Hirzebruch M., Schmidt E. K., von Unruh G. E., Dengler H. J. Pharmacokinetics of prenylamine racemate and enantiomers in man. Drug Res. 1990; 40: 657–661
   Web of Science ®Google Scholar
• Remberg G., Eichelbaum M., Spiteller G., Dengler H. J. Metabolism of DL- [14C]prenylamine in man. Biomed. Mass Spectrom. 1977; 4: 297–304
   PubMedGoogle Scholar
• Gietl Y., Spahn H., Mutschler E. Simultaneous determination of R- and S-prenylamine in plasma and urine by reversed-phase high-performance liquid chromatography. J. Chromatogr. 1988; 426: 304–314
   PubMedGoogle Scholar
• Gietl Y., Spahn H., Mutschler E. Enantioselective disposition of R-(−)- and S-(+)-prenylamine in the rat. Drug Res. 1989; 39: 853–856
   Web of Science ®Google Scholar
• Schmidt E. K., von Unruh G. E., Paar W. D., Dengler H. J. A gas chromatographic/mass spectrometric assay for prenylamine suitable for pharmacokinetic studies of the racemate and the enantiomers. Biol. Mass Spectrom. 1992; 21: 103–108
   PubMedGoogle Scholar
• Hornke I., Hajdu P. Studies on the metabolism of prenylamine in rats. Drug Res. 1970; 20: 791–794
   Web of Science ®Google Scholar
• Palm D., Fengler H., Grobecker H. Urinary excretion of amphetamine in man after administration of prenylamine. Life Sci. 1969; 8: 247–257
   PubMed Web of Science ®Google Scholar
• Palm D., Grobecker H., Fengler H. Metabolism of prenylamine (Segontin), Naunyn Schmiedeberg's. Arch. Exp. Pathol. Pharmacol. 1968; 260: 185–186
   PubMedGoogle Scholar
• Iwersen S., Schmoldt A. One fatal and one nonfatal intoxication with tranylcypromine. Absence of amphetamines as metabolites. J. Anal. Toxicol. 1996; 20: 301–304
   PubMed Web of Science ®Google Scholar
• Jefferson J. W. Is tranylcypromine really metabolized to amphetamine?. J. Clin. Psychiatry 1992; 53: 450–451
   PubMed Web of Science ®Google Scholar
• Mori A., Ishiyama I., Akita H., Suzuki K., Mitsuoka T., Oishi T. Formation of amphetamine from its nitro analogue by anaerobic intestinal bacteria. Xenobiotica 1990; 20: 629–634
   PubMed Web of Science ®Google Scholar
• Nakahara Y. Detection and diagnostic interpretation of amphetamines in hair. Forensic Sci. Int. 1995; 70: 135–153
   PubMed Web of Science ®Google Scholar
• Nakahara Y., Takahashi K., Kikura R. Hair analysis for drugs of abuse. X. Effect of physicochemical properties of drugs on the incorporation rates into hair. Biol. Pharm. Bull. 1995; 18: 1223–1227
   PubMed Web of Science ®Google Scholar